Stock 603368 GUANGXI LIUYAO GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangxi LiuYao Group Co., Ltd

Equities

603368

CNE100001VR3

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
23.34 CNY -1.89% Intraday chart for Guangxi LiuYao Group Co., Ltd +2.59% +23.36%
04-25 Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-22 Guangxi Liuyao Gets Shanghai Bourse's Nod to Issue Shares MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGXI LIUYAO GROUP CO., LTD Stock Guangxi LiuYao Group Co., Ltd
+23.36% 1.3B -
MCKESSON CORPORATION Stock McKesson Corporation
+19.13% 71.7B
C+
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-3.66% 23.73B
C+
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+8.80% 9.01B
C
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+11.24% 8.72B
B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-18.91% 8.29B
B-
H. LUNDBECK A/S Stock H. Lundbeck A/S
+16.00% 5B
B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.83% 4.48B
B+
EBOS GROUP LIMITED Stock EBOS Group Limited
-2.11% 4.08B
B-
GALENICA AG Stock Galenica AG
-1.72% 3.92B
B
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603368 Stock
  4. Ratings Guangxi LiuYao Group Co., Ltd